Skip to main content

Table 1 Perinatal characteristics, short-term morbidities and neurodevelopmental outcomes of infants classified by presence of HsPDA

From: Retrospective comparison of death or neurodevelopmental outcomes in extremely low birth weight preterm infants following different management options of haemodynamically significant patent ductus arteriosus

  Non-HsPDA
n = 48
HsPDA
n = 124
n (%)/mean ± SD n (%)/mean ± SD P value
GA (weeks) 27.3 ± 0.8 26.2 ± 1.3 0.000
BW (g) 1009.8 ± 212.1 889.6 ± 190.6 0.000
APGAR (5 min) < 7 10 (21.3) 14 (11.9) 0.12
CRIB II > 12 5 (10.6) 33 (26.8) 0.023
Severe RDS Grade 2–4 11 (22.9) 85 (68.5) 0.000
Surfactant Therapy > 2 doses 1 (2.1) 16 (12.9) 0.033
Sepsis 6 (12.5) 38 (30.6) 0.014
Severe IVH Grade 3–4 5 (10.4) 25 (20.2) 0.13
PVL 1 (2.1) 4 (3.2) 0.69
NEC or NEC with complication/surgery 0 (0.0) 8 (6.5) 0.07
Threshold ROP Stage 3–4 1 (2.4) 24 (21.1) 0.005
CLDa 34 (81.0) 71 (62.8) 0.032
Weight at Discharge z-score −1.8 ± 1.1 −2.8 ± 1.2 0.000
Length at Discharge z-score −2.1 ± 1.2 −3.6 ± 1.4 0.000
Head circumference at Discharge z-score −0.8 ± 1.5 −2.0 ± 1.0 0.000
Death or GDD 37 (77.1) 89 (72.4) 0.53
CP 1 (2.4) 10 (9.0) 0.16
Abnormal hearing test at discharge 1 (2.4) 8 (7.1) 0.26
Hearing loss requiring hearing aids or implants 0 (0.0) 7 (6.3) 0.10
Isolated speech delay 2 (4.8) 19 (17.1) 0.047
  1. aWe assumed the worst case scenario that infants who died prior to 36 weeks developed CLD